Worldwide Biotech & Pharmaceutical

Worldwide Biotech & Pharmaceutical Co. (WWBP) was a biotechnology company primarily focused on the research, development, and commercialization of products for the Hepatitis C Virus (HCV). Based in Xi'an, China, the company gained prominence for its proprietary technology to culture intact HCV in vitro, which it used to develop diagnostic kits and potential therapeutic candidates. Its lead product was a diagnostic kit for Hepatitis C antibody detection (ELISA) approved by the Chinese SFDA in 2007. The company operated through its subsidiary, Yangling Daiying Biotech & Pharmaceutical Group, and was publicly traded on the OTC Bulletin Board. However, the company faced regulatory challenges and its SEC registration was eventually revoked due to delinquent filings.